Lisata Therapeutics, Inc. (LSTA) is a Healthcare stock trading at $1.67 (as of 2026-07-24), with a market capitalization of $15.21M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics develops and commercializes cellular therapies, with product candidates in Phase II and Phase IIb clinical trials, aiming to treat conditions by reversing disease and promoting regeneration of damaged tissue.
Because Lisata is a clinical-stage biopharmaceutical company developing cellular therapies through Phase II and Phase IIb trials, its path to profit depends on trial execution and clinical efficacy signals that can support moving candidates toward commercialization (with recent reported revenue at 0.0B).
Business quality (Weak): The key watch items are how its trials progress (enrollment and completion) and whether reported efficacy signals compare favorably versus control groups, but investors also face high development risk and a deeply negative operating margin.
| Price | $1.67 |
| Market Cap | $15.21M |
| Price / Book | 1.43 |
| Price / Sales | 63.37 |
| FCF Yield | -46.1% |
| Revenue (TTM) | $170000.00 |
| Net Margin | -9756.5% |
| Return on Equity | -153.2% |
| Current Ratio | 4.23 |
| Revenue Growth (YoY) | -83.0% |
| EPS Growth (YoY) | -20.4% |
| FCF Growth (YoY) | -17.5% |
| Altman Z-Score | -44.04 (distress) |
| Sector P/E (Healthcare) | 21.2 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | VANGUARD CAPITAL MANAGEMENT LLC ($1.36M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | David J. Mazzo |
| Employees | 26 |
| Country | US |
| IPO Date | 1999-03-01 |
Data as of 2026-07-24.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.